NCT07054567View on ClinicalTrials.gov

A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

December 31, 2027

Conditions
Cervical CancerEndometrial Cancer
Interventions
DRUG

BL-B01D1

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

Pembrolizumab

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

Bevacizumab

Administration for a cycle of 3 weeks.

Trial Locations (1)

Unknown

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY